mbilusic Profile Banner
Marijo Bilusic, MD, PhD Profile
Marijo Bilusic, MD, PhD

@mbilusic

Followers
775
Following
738
Media
9
Statuses
326

Professor, GU Medical Oncologist interested in #immunotherapy #cancerresarch #ProstateCancer @SylvesterCancer @umiamihealth. All views are my own.

Miami, FL
Joined April 2009
Don't wanna be here? Send us removal request.
@mbilusic
Marijo Bilusic, MD, PhD
4 years
I'm excited to start a new chapter.
@SylvesterCancer
Sylvester Comprehensive Cancer Center
4 years
Let's give Dr. Marijo Bilusic a warm welcome this morning! @mbilusic recently joined #SylvesterCancer as Leader of the Genitourinary Cancers Site Disease Group and will hold clinic sessions in #Miami. Read more: #NCI #NIH.
12
2
60
@mbilusic
Marijo Bilusic, MD, PhD
1 month
RT @SylvesterCancer: We had the honor of inviting Sylvester patient Donica Stephens to join us at the @Marlins Prostate Cancer Awareness Ga….
0
4
0
@mbilusic
Marijo Bilusic, MD, PhD
6 months
RT @urotoday: #Metformin study reveals weight management benefits for ADT therapy. @Silke_Gillessen and @neerajaiims discuss the results of….
0
9
0
@mbilusic
Marijo Bilusic, MD, PhD
6 months
Hot off the press. Overcoming common emerging barriers to effective neoadjuvant immunotherapies: Expert Review of Anticancer Therapy: Vol 0 , No ja - Get Access
Tweet card summary image
tandfonline.com
Neoadjuvant immunotherapy has rapidly evolved as a novel approach in oncology, reshaping the standard treatment for several malignancies, including melanoma, lung, bladder, colorectal, and breast c...
0
2
7
@mbilusic
Marijo Bilusic, MD, PhD
6 months
RT @Dr_RaviMadan: Abs#45 @asco #GU25. Prelim data shows near term metastatic progression (conventional imaging) is a rare event in #PSMA+ #….
0
15
0
@mbilusic
Marijo Bilusic, MD, PhD
9 months
RT @Dr_RaviMadan: “Truqap combination (w/abiraterone) in #PTEN -deficient #mCSPC #ProstateCancer demonstrated statistically significant & c….
astrazeneca.com
0
7
0
@mbilusic
Marijo Bilusic, MD, PhD
1 year
We are hiring a postdoc. If you want to learn more/apply please visit.
0
1
5
@mbilusic
Marijo Bilusic, MD, PhD
1 year
RT @Cancer_Cell: Online Now: Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic cas….
0
53
0
@mbilusic
Marijo Bilusic, MD, PhD
1 year
I received a $100.00 donation supporting Dolphins Challenge Cancer!
0
0
1
@mbilusic
Marijo Bilusic, MD, PhD
2 years
I received a $100.00 donation supporting Dolphins Challenge Cancer!
0
0
5
@mbilusic
Marijo Bilusic, MD, PhD
2 years
I received a $50.00 donation supporting Dolphins Challenge Cancer!
0
0
1
@mbilusic
Marijo Bilusic, MD, PhD
2 years
I received a $50.00 donation supporting Dolphins Challenge Cancer!
0
0
0
@mbilusic
Marijo Bilusic, MD, PhD
2 years
RT @Latinamd: Where the magic ✨happens at @SylvesterCancer Experimental Therapeutics/Phase 1 Clinic this morning with @mbilusic .@JaimeMerc….
0
5
0
@mbilusic
Marijo Bilusic, MD, PhD
2 years
RT @EurUrolOncol: Articles in Press: Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration….
0
9
0
@mbilusic
Marijo Bilusic, MD, PhD
2 years
RT @SylvesterCancer: #Genetic testing could be a game changer when it comes to #cancer testing and prevention. Learn from Sylvester #oncolo….
Tweet card summary image
news.med.miami.edu
Sylvester Comprehensive Cancer Center researchers say genetic testing identifies "previvors" at higher risk for cancer.
0
4
0
@mbilusic
Marijo Bilusic, MD, PhD
2 years
I received a $200.00 donation supporting Dolphins Challenge Cancer!
0
0
4
@mbilusic
Marijo Bilusic, MD, PhD
2 years
I received a $250.00 donation supporting Dolphins Challenge Cancer!
1
0
2
@mbilusic
Marijo Bilusic, MD, PhD
2 years
I received a $50.00 donation supporting Dolphins Challenge Cancer!
0
0
2
@mbilusic
Marijo Bilusic, MD, PhD
2 years
I donated in support of Dolphins Challenge Cancer!
0
0
1
@mbilusic
Marijo Bilusic, MD, PhD
2 years
RT @AnaBaracCardio: Exciting @CroAmPro #ACAP2023 in Zagreb. panel discussions on partnerships in clinical trials with terrific insights by….
0
2
0